Human Immunoglobulin(pH4) (Xinjiang Deyuan Biological Engineering)

人免疫球蛋白(pH4)（新疆德源生物工程）

Report date: 2022/01/14 13:23:58

Base Information

Drug NameHuman Immunoglobulin(pH4) (Xinjiang Deyuan Biological Engineering)
Drug Alias NameN/A
ClassificationBiologics > Protein drugs > ImmunoglobulinBiologics > Blood components
Mechanisms of ActionImmunomodulators
TargetsNot applicable
Therapy Area/IndicationsPurpura, Thrombocytopenic, Idiopathic
Global Approved IndicationsPurpura, Thrombocytopenic, Idiopathic
Approved Indications in ChinaPurpura, Thrombocytopenic, Idiopathic
Original Approved Country/TerritoryMainland China
Original Approved Date2020/07/16
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesXinjiang Deyuan Biological Engineering Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesXinjiang Deyuan Biological Engineering Co Ltd
Inactive CompaniesN/A
Active IndicationsPurpura, Thrombocytopenic, Idiopathic
Inactive IndicationsN/A

Other Information

ATC CodeJ06BA02
Related LinksN/A